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ABSTRACT
Huntington’s disease (HD) is a fatal autosomal dominant
neurodegenerative disease involving progressive motor,
cognitive and behavioural decline, leading to death
approximately 20 years after motor onset. The disease is
characterised pathologically by an early and progressive
striatal neuronal cell loss and atrophy, which has
provided the rationale for ﬁrst clinical trials of neural
repair using fetal striatal cell transplantation. Between
2000 and 2003, the ‘NEST-UK’ consortium carried out
bilateral striatal transplants of human fetal striatal tissue
in ﬁve HD patients. This paper describes the long-term
follow up over a 3–10-year postoperative period of the
patients, grafted and non-grafted, recruited to this
cohort using the ‘Core assessment program for
intracerebral transplantations-HD’ assessment protocol.
No signiﬁcant differences were found over time between
the patients, grafted and non-grafted, on any subscore
of the Uniﬁed Huntington’s Disease Rating Scale, nor on
the Mini Mental State Examination. There was a trend
towards a slowing of progression on some timed motor
tasks in four of the ﬁve patients with transplants, but
overall, the trial showed no signiﬁcant beneﬁt of striatal
allografts in comparison with a reference cohort of
patients without grafts. Importantly, no signiﬁcant
adverse or placebo effects were seen. Notably, the
raclopride positron emission tomography (PET) signal in
individuals with transplants, indicated that there was no
obvious surviving striatal graft tissue. This study
concludes that fetal striatal allografting in HD is safe.
While no sustained functional beneﬁt was seen, we
conclude that this may relate to the small amount of
tissue that was grafted in this safety study compared
with other reports of more successful transplants in
patients with HD.
INTRODUCTION
Huntington’s disease (HD) is an inherited, progres-
sive neurodegenerative disorder characterised by
involuntary movements, psychiatric and cognitive
symptoms and signs. It is caused by an expansion of
the CAG repeat in exon 1 of the huntingtin (htt)
gene. Patients with 36 or more CAG repeats in this
gene develop HD. Htt is now recognised to be
involved in a variety of cellular, metabolic, transcrip-
tion and maintenance processes throughout develop-
ment and in the adult.1 2 Abnormal CAG expansion
in HD results in neuronal dysfunction, aberrant intra-
cellular aggregation of mutant protein fragments and,
eventually, cell death. Cellular dysfunction and loss is
regionally speciﬁc within the brain, with early prom-
inent atrophy occurring within the caudate nucleus
and putamen, as well as the neocortex, and eventu-
ally extending to additional areas of the brain with
advancing disease.3 The condition is currently incur-
able with the patient usually dying within
15–30 years of disease onset.4 5
Current therapies provide only partial relief of
some of the symptoms of HD, and no disease-
modifying therapies are yet available. One experi-
mental therapeutic strategy has been to seek to
replace the damaged and dying cells of the striatum
with fetal striatal transplants, with some beneﬁts
reported in initial small studies.6–8 These studies
reported motor and cognitive improvements and
stabilisation over 5–6 years, consistent with data
from positron emission tomography (PET) scans
showing striatal metabolic activity at the site of
graft placement.7–10 However, improvement has
not been consistent in all studies, and the safety of
such transplants, at least in patients with advanced
disease, has been questioned11 12 (see refs 13 and 14
for discussion).
The NEST-UK multicentre study was initiated in
1998 as the second of two European centres to
evaluate the safety and efﬁcacy of bilateral fetal stri-
atal transplantation in HD (ISRCTN no
36485475).15 This pilot study was designed to
evaluate the feasibility, as well as providing prelim-
inary data on the tolerability, of serial bilateral stri-
atal transplantation in 10 patients with mild HD.
The study was designed as a learning rather than a
conﬁrming trial and, as such, sought to describe
what was seen, rather than being powered to show
an effect. In this last issue, a conﬁrmatory study
would need to be much larger as our study only
has an effect size of 0.74, so is not (and was not
intended to be) powered to formally assess efﬁcacy.
If the trial had been designed for this purpose, then
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a further 21 patients would be needed in the transplant arm to
detect a clinically meaningful difference of ﬁve points on the
Uniﬁed Huntington’s Disease Rating Scale (UHDRS) motor
scale at 10–12 years postsurgery.
The operations were undertaken in ﬁve patients between
2000 and 2003. A preliminary report of safety of the surgical
procedures has been published from the ﬁrst four patients after
unilateral transplantation.15 Following this, the second phase of
the trial commenced, in which these patients received contralat-
eral transplants, and one additional patient received simultan-
eous bilateral transplants. At that time, the European Union
published the Tissue and Cells directive,16 which required that
full pharmaceutical-grade standards be applied to the processing
of all cells and tissues for human application, including in small
academic pilot studies. Implementation of the tissue directive
into UK regulation led to suspension of the NEST-UK trial,
pending full compliance with the new European standards, and
this process is still ongoing. Since the completion date for the
original study is further extended for at least 4 years, we con-
sider that progress in the ﬁrst ﬁve patients with grafts is inform-
ative, in comparison with 12 HD patients without grafts
included in the initial cohort, and warrants an interim report,
which we present here.
METHODS
Full details of the methods can be found in Rosser et al,15 17
brieﬂy given in what follows.
Patient cohort
Initial plans for fetal cell transplantation in HD originated from
the European Biomed network for striatal transplantation in HD
(NEST-HD) in 1990–1993. The NEST-HD program coordinated
a series of preclinical experimental studies18–21 and established a
core assessment protocol for the longitudinal evaluation of
patients within transplant trials (Core Assessment Program for
Intracerebral Transplantations (CAPIT)-HD).22 The UK arm of
this program was established as a collaboration between six
centres (NEST-UK: Belfast, Aberdeen, Manchester, Cardiff,
Cambridge, London) coordinated from Cambridge, with recruit-
ment into the longitudinal assessment cohort taking place from
1994 to 2000. Separate ethical permission for undertaking trans-
plantation was granted in 1999 (approval number: 99/099M) to
commence a clinical trial of the safety and feasibility of fetal stri-
atal transplantation. The ﬁrst ﬁve patients were all selected for
grafting from the Cambridge cohort of 17 patients recruited into
the CAPIT-HD longitudinal assessment program. The present
report is based on 8–10 years progression in these ﬁve patients,
in comparison with the 12 patients from the longitudinal cohort
who were assessed as being equally suitable for transplantation,
but who were not randomly selected for the surgery.
Trial design
Following discussion and endorsement with the Cambridge
research ethics committee, we adopted the following patient
selection protocol. Within the Cambridge cohort of 17 patients,
ﬁve patients were randomly selected to receive a transplant. In
2000–2001, the ﬁrst four patients received unilateral transplants
of fetal striatal cells into the striatum, followed by a second
transplant operation on average 22.5 (±3.9) months later into
the contralateral striatum. The ﬁfth patient received simultan-
eous bilateral striatal allografts in 2003. Characteristics of both
the individual patients with transplants and of the reference
cohort are shown in table 1. All patients have been followed
longitudinally for 10 years or more using the full CAPIT-HD
protocol, with 6-monthly neurological and behavioural assess-
ments, annual neuropsychological assessments and periodic
brain imaging (see below), with additional quantitative neuro-
logical and automated neuropsychological assessments (see
below). All assessments were undertaken ‘open label’, without
blinding of patients or clinicians to the treatment.
Tissue preparation and neurosurgical procedures
Full details of tissue procurement, preparation, immunosuppres-
sion, safety assessment and implantation of the ﬁrst four unilat-
eral implants has been fully reported elsewhere.15 17 23 24 The
present report is based upon the progress of these same four
patients following their second, contralateral implant, and a
ﬁfth patient who received bilateral transplants in a single surgi-
cal session, following the same protocols. Surgical and donor
tissue parameters are shown in table 2. Doses of the three
immunosuppressant drugs were slowly withdrawn a year after
the second transplant.
Clinical assessment
All patients underwent a longitudinal assessment which included
the full CAPIT-HD protocol22 plus additional motor and cogni-
tive assessments. UHDRS26 motor, functional, behavioural and
cognitive scales; and the following timed motor tests, 12 m
walking, hand tapping in 30 s27 and time to drink 120 ml of
water, were assessed at 6-month intervals: The UHDRS cogni-
tive scale, the extended CAPIT-HD cognitive battery, and add-
itional automated cognitive neuropsychological assessments28
were undertaken annually (see table 1). The ﬁve patients with
transplants had pre- and postsurgical MRI and raclopride PET
scans. 11C-raclopride (RAC) PETwas carried out at baseline and
after transplantation for 1–2 years postgrafting to assess striatal
dopamine D2 receptor status and graft survival, assuming the
grafts contained mature/differentiated striatal tissue which
would express such receptors.8 The PET scanning protocol is as
described previously.29 Six of the patients without transplants
Table 1 Patient characteristics at time of recruitment
Measure Transplant Controls t15*
n 5 12
Sex (M:F) 4 : 1 8 : 4
Age at recruitment 43.4±1.5 47.2±2.7 2.11
Age at transplant 48.0±1.5 51.1±2.1 0.88
Education age 13.8±0.69 12.3±0.7 1.27
UHDRS 23.4±6.0 19.3±3.2 −0.87
Total functional assessment 27.0±0.7 26.2±0.5 0.80
Total functional capacity 10.4±0.8 10.8±0.6 0.36
Independence score 94.0±1.6 94.6±3.2 0.11
Mini mental state exam 28.8±0.3 27.8±0.7 0.88
WAIS (vocab) 11.2±0.8 10.1±0.7 −1.45
WAIS (block design) 11.0±1.2 10.7±0.7 −0.33
NART 115.0±1.1 109.6±2.1 −3.19*
VOSP battery (total score) 132.6±2.8 129.8±3.3 −0.93
VOSP battery (n of pass) 1.0±0.6 1.3±0.4 0.62
Boston naming test 28.0±0.4 26.8±0.4 −2.80
Token test 33.8±0.9 32.7±0.5 −1.53
*All differences are non-significant at p>0.10, with the exception of the NART scores,
p<0.01.
N.B: As patient recruitment took place more than 12 years ago, while genetic
confirmation of the HD gene expansion was obtained for all participants, the exact
CAG repeat length was not documented in many cases.
UHDRS, Unified Huntington’s Disease Rating Scale; WAIS, Wechsler Adult Intelligence
Scale; VOSP, visual object and space perception battery; NART, National Adult
Reading Test.
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also received RAC PET and acted as the controls for the patients
with transplants.
Most patients have been assessed over 10–15 years; 3–5 years
prior to and 7–10 years following the transplant selection
period. Full details of all tests are provided in both the supple-
mentary materials (information about participants drug regimes
(see online supplementary table S1), psychiatric assessment and
automated neuropsychological assessment on the CANTAB
testing battery (see online supplementary table S2) and in the
methods section.
Statistical analyses
The ﬁve patients with transplants are compared with the remain-
ing 12 patients recruited into the longitudinal NEST-HD cohort,
and similarly available for selection for transplantation prior to
trial suspension (‘Reference control group’). Surgery in the
patients with transplants was undertaken approximately 4–5 years
following recruitment into the programme and all longitudinal
data is referenced to the date of ﬁrst transplantation (=T0). The
patients selected for transplant surgery were slightly younger with
higher UHDRS motor scores than the remainder of the reference
group at the time of ﬁrst recruitment, although these differences
were not signiﬁcant (table 3). The only signiﬁcant difference
between the two groups was the National Adult Reading Test
(NART) scores which suggested that the group with transplants
had slightly higher premorbid IQ (table 1, t15=3.11, p<0.01), but
with no correction for multiple comparisons.
For longitudinal analysis of progression in control patients,
T0 was designated as 4 years following ﬁrst recruitment into the
programme (although other arbitrary time shifts have no effect
on the results).
According to the CAPIT protocol, neurological assessments
were undertaken at 6-monthly intervals, and neuropsychological
assessments at yearly intervals, although there were inevitably
small variations in the precise scheduling of tests, and occasional
missed assessments (less than 5% overall). For purposes of ana-
lysis, the scores on each test were averaged for each patient in
2-year blocks over 12 years, referenced with regard to >2 years
pre-T0, 2–0 years prior to T0, and in 2-year blocks up to 6–
8 years following T0. Longitudinal progression of impairments
on each neurological and neuropsychological test was analysed
by a two-factor analyses of variance (Genstat v.11, VSN
International, Hemel Hempstead). Missing values were entered
in the dataset for patients who died or withdrew before the end
of the 12-year assessment window, or where consecutive tests
were omitted. The Genstat analysis programme is powered to
estimate missing values by an iterative minimum variance
routine that reduces the degrees of freedom in the estimates of
error variance to correct for regression towards the mean,
allowing unbiased inclusion of all patients’ data.
RESULTS
Demographics: adverse events
There were no major adverse events, in line with the initial
safety report on the ﬁrst four patients receiving unilateral trans-
plants of fetal striatal tissue.15
The patients all showed a transient and anticipated decline in
renal function post-transplantation, secondary to the cyclospor-
ine immunotherapy they were receiving. This resolved when the
treatment was eventually discontinued. Immunosuppression was
also thought to be responsible for a transient anaemia in Patients
1 and 3, which again resolved on stopping the medication.
Soon after the second transplant, Patient 3 experienced a
problem with lumbar disc disease, but this spontaneously
resolved without recourse to surgery.
Table 3 Demographics of patients, grafted and non-grafted. The table shows the age at time of operation (for patients without grafts, the
time of surgery is taken as May of the year 2000; which is the average date of the operations of the first four patients) along with their disease
characteristics
Group Age
M:
F
Duration of disease at time
of first surgery (years)
Duration of disease at
last assessment
UHDRS total motor
score at surgery
Last recorded UHDRS total motor
score (months after first graft)
Patient 1 50 F 7 17 31 37 (120 mo)
Patient 2 52 M 9 15 46 58 (108 mo)
Patient 3 53 M 7 16 32 66 (96 mo)
Patient 4 45 M 6 15 78 87 (36mo)
Patient 5 44 M 4 10 12 25 (78 mo)
Patients with grafts
average
48.8
±14.6
4 :
1
6.6±0.8 14.6±1.2 39.8±10.9 54.6±10.9
Patients
withoutgrafts average
49.8
±2.02
8 :
4
7.2±2.4 14.9±3.5 27.9±14.0 40.5±19.7
It should be noted that the UHDRS motor scores, especially the last recorded scores of the patients without grafts were very variable; ranging from 17 to 79 (maximum score is 124).
UHDRS, Unified Huntington’s Disease Rating Scale
Table 2 Details of the right- and left-sided-placed transplants in
each patient—number of fetuses/ganglionic eminences, fetal age/
stage/CRL, number of cells implanted, number and location of graft
tracks in caudate and in putamen, number of deposits per track
Group Transplant
Number
of
fetuses
Number
of cells
(millions)
Number
of tracts
Number of
cells per
deposit per
tract
(per ml)
Patient 1 1 1 6.59 6 94 000
2 1 6.2 6 103 333
Patient 2 1 1 11.14 5 139 250
2 1.5 12.2 6 203 000
Patient 3 1 1 6.1 4 Not
recorded
2 1 6 m 6 100 000
Patient 4 1 1 7.1 m 5 101 429
2 1 12.2 m 6 203 333
Patient 5 1 and 2 2 5.9 m 6 99 375
The differences in numbers of cells grafted varies depending on the amount and age
of fetal material available at the time of grafting.
CRL, crown rump length.
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Patient 1 developed a renal cell carcinoma following the ﬁrst
transplant which was resected with no residual tumour and no
metastatic spread. The occurrence of this tumour was thought
to be unrelated to either the transplant or immunosuppressive
medication, and as such, the patient completed a full course of
immunosuppression following the second transplant without
any adverse events.
Clinical assessment
An average of 22.5 months after the ﬁrst transplant, patients 1,
2, 3 and 4 had a second transplant to the contralateral striatum.
The ﬁrst three of these patients then continued to attend for
regular assessments for the next 5 years. Patient 4 was unable to
attend further appointments after 2005, 2 years after his second
transplant. He died on 25 December 2009; the cause of death
was recorded as aspiration pneumonia. No postmortem was
conducted, nor unfortunately, was the brain collected for ana-
lysis. Patient ﬁve received a bilateral transplant and is still being
followed-up 6 years after his operation. Details of drug treat-
ments and performance on assessments additional to the
CAPIT-HD protocol are included in the supplementary data.
Motor assessments
UHDRS total motor score
The total UHDRS motor score of the ﬁve patients with trans-
plants was compared with that of the 12 patients without grafts.
Over a 13-year follow-up, the UHDRS score increased progres-
sively in all patients, signifying a slow progressive worsening of
motor signs (ﬁgure 1). The best ﬁt regression lines to the annual
means of each group indicated a highly signiﬁcant rate of
disease progression in both groups (Transplant, r=0.628,
t12=2.80, p<0.02; Reference controls, r=0.708, t12=3.47.
p<0.01), and the slopes of the best regression ﬁts in the two
groups did not differ.
Analysis of individual patients revealed some apparent
improvements. Thus, Patient 1 showed improvement after the
ﬁrst unilateral transplant, with the UHDRS motor score falling
from 37 to 18 in the ﬁrst 6 months after transplantation. After
the second transplant, (at T=22.5 on the graph) the UHDRS
motor scores became and continued to get progressively worse.
The ﬁnal UHDRS score recorded 10 years after the ﬁrst trans-
plant was 37. This patient has never received any drug treat-
ment for her chorea. Patient 2 also improved his motor score
after the ﬁrst transplant and again after the second operation,
and for the next 6 years their motor UHDRS score seemed to
stabilise. Motor scores, however, then deteriorated and have
continued to do so to the present time, and olanzapine was
started for psychiatric problems 7 years after the initial trans-
plant. However, some individual patients in the reference
control group showed equally marked improvements at particu-
lar points during the course of their 6-monthly, or annual assess-
ments (see ﬁgure 1). Thus, we see no evidence when comparing
all patients of the two groups of a signiﬁcant short-term
improvement following transplantation, and no evidence for a
change of slope of disease progression. Importantly, there is also
no evidence of a detectable placebo effect in the transplant
group when using objective motor ratings in the UHDRS, even
though this is an open label trial design.
Full CAPIT neurological assessment
Neurological assessments were conducted at 6-monthly intervals
according to the CAPIT protocol. For purposes of analysis, the
scores on each test were averaged for each patient in 2-year
blocks over 12 years, referenced with regard to >2 years pre-T0,
2–0 years prior to T0, and in 2-year blocks up to 6–8 years fol-
lowing T0. As shown in table 4, all test measures showed a clear
and very highly signiﬁcant (Years, F5,69=6.20–39.31, all
p<0.001) worsening over time. However, none of the tests
showed any difference between the transplant and reference
control groups, either overall, nor following transplant surgery,
with the sole exception of the timed walk subtest, in which the
interaction term reached signiﬁcance if no correction is made for
multiple testing (Groups×Years, F5,69=2.67, p<0.05). However,
although it does appear that the group with transplants shows a
slowing of impairment on this one test, the only signiﬁcant differ-
ence relates to the last time point 10–12 years after initial recruit-
ment 6–8 years postsurgery, and not in the period immediately
following transplantation.
Full CAPIT neuropsychological assessment
Progression of performance in the neuropsychological test
battery was similarly analysed, combining each patient’s mean
performance in 2-year blocks. As shown in table 5, and similar
to the neurological measures, 20 of the 21 tests showed highly
signiﬁcant progression over the 12 years of repeated assessments
(Years, F5,69=4.63–44.63, all p<0.001), the only exception
being the Rivermead test of recognition memory, which showed
very little impairment in either group even in the advanced
patients. Again, none of the tests showed any signiﬁcant differ-
ences between patients with transplants and reference controls,
either overall or in terms of a differential response following
transplantation, with the sole exception of the categories sub-
measure of the Wisconsin Card Sorting test, on which the
remaining patients with transplants showed differentially poorer
performance on the ﬁnal test 6–8 years postsurgery
Figure 1 Annual Uniﬁed Huntington’s Disease Rating Scale total
motor scores from 3 years prior to and up to 10 years following the
time of the ﬁrst transplant surgery in the ﬁve patients with grafts, and
in the 12 reference control patients synchronised with the stage at
which they would have received transplants if the programme had been
able to continue. *The ﬁrst four transplant cases (TP1-4) received serial
transplant surgeries on the two sides at times T1 and T2 separated by
approximately 2 years, whereas TP5 received a single bilateral surgery
at T1. The bold line indicates the best ﬁt linear regression applied to
the ﬁve transplant cases (solid) and separately to the 12 controls
(dashed). Note that the separation between the two lines is fully
attributable to the one transplant case TP4, whose Uniﬁed
Huntington’s Disease Rating Scale scores were signiﬁcantly higher than
any other case in the cohort, whereas the slope of the two regression
lines, indicating rate of disease progression in the two groups, do not
differ.
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(Groups×Years, F5,69=4.52, p<0.001, uncorrected for multiple
comparisons). By contrast to the conventional neuropsycho-
logical tests, we found the CANTAB automated touch screen
measures to be less sensitive to the longitudinal progression of
the disease (see supplementary table 2).
Imaging
MRI
Postoperative MRI scans conﬁrmed appropriate surgical target-
ing with increased FLAIR signal along the implantation tracts.
No occult haemorrhage was identiﬁed. Subsequent imaging was
unable to identify any implanted material, and there were no
mass lesions seen to develop in or around the transplant site.
No volumetric studies were undertaken as MRI was employed
for safety assessments only. All patients continued to have
increased ventricular volume after the transplants, but as we did
not collect data on ventricular volume prior to transplantation,
nor on patients without grafts, we cannot conclude anything
further with respect to how the transplants affected striatal or
whole brain atrophy.
PET
As the ﬁrst four surgical subjects received implantation into the
right striatum initially, their left striatal binding potential (BP)
acted as an internal control for the contralateral side prior to
the second implantation. Averaging the PET results of the ﬁrst
four subjects who received unilateral transplants, the rates of
decline of striatal RAC BP were slightly higher on the right
(transplanted side) after the ﬁrst implantation, but this differ-
ence disappeared after the second implantation. The overall
rates of progression from baseline to 1 year after the second
operation were similar on both sides, and were not signiﬁcantly
different from those of non-grafted HD controls (ﬁgure 2), in
line with previous longitudinal studies in HD using this ligand.
Subject 5 was scanned using a different PET camera and
hence, his data could not be compared directly with the rest.
The rates of progression of his striatal RAC BP at 1 year post-
transplantation were 8.9% and 7.3% per annum for the right
and left sides respectively. He did not receive further RAC PET
scans as he was started on quetiapine for a psychotic episode,
which interferes with RAC binding.
DISCUSSION
This study reports the long-term safety, motor, cognitive and
psychiatric effects of bilateral fetal striatal allotransplants in ﬁve
patients with mild to moderate HD, in comparison with a refer-
ence group of 12 patients from the same cohort who were simi-
larly suitable for transplantation but not selected for surgery,
but were followed in an identical way.
There were no signiﬁcant differences in any of the measures
chosen when comparing patients with transplants with this ref-
erence cohort at baseline and followed-up for up to 10 years
postsurgery, using identical protocols of assessment. In small
open label studies with multiple outcome measures, it is
Table 4 CAPIT UHDRS and motor assessments
0–2 years
(2–4 years
pre-T1)
2–4 years
(0–2 years
pre-T0)
4–6 years
(0–2 years
post-T0)
6–8 years
(2–4 years
post-T0)
8–10 years
(4–6 years
post-T0)
10–12 years
(6–8 years
post-T0) Groups Time Group×Time
Tests Years Mean±SEM Mean±SEM Mean±SEM Mean±SEM Mean±SEM Mean±SEM F1,15 F5,69 F5,69
UHDRS (total
motor scale)
Control 20.3±3.2 27.9±3.8 32.4±3.8 33.3±3.9 37.4±5.7 42.1±6.8 1.16 26.38** 0.87
Transplant 26.3±7.2 39.0±9.7 38.7±11.1 44.2±12.3 35.8±5.4 46.0±7.9
UHDRS (functional
assessment)
Control 14.1±2.5 19.7±2.9 21.7±2.5 22.4±2.8 27.4±4.7 32.8±6.0 1.00 14.80** 0.62
Transplant 19.5±5.0 28.0±8.1 27.3±10.4 31.6±12.8 22.7±5.9 35.3±9.1
UHDRS (ADL
scale)
Control 23.6±0.6 22.5±0.9 21.9±1.0 19.9±1.5 17.3±2.3 16.4±3.0 0.15 12.37** 0.47
Transplant 23.2±0.9 22.3±1.0 22.1±0.8 18.0±3.1 18.4±2.2 14.3±3.5
UHDRS
(independence
scale)
Control 92.4±2.9 86.6±3.2 83.2±3.0 77.8±3.1 72.5±4.7 66.6±6.1 0.23 26.14** 0.43
Transplant 91.7±3.9 85.6±3.9 83.1±3.6 72.8±8.1 72.6±4.3 63.9±7.1
Fahn score Control 10.37±0.76 9.62±0.79 8.97±0.77 7.97±0.94 6.99±1.09 6.07±1.33 0.44 15.42** 0.28
Transplant 9.68±0.98 8.42±1.34 8.78±0.90 7.18±1.41 6.08±1.43 5.13±2.19
Cognitive battery
(total scores)
Control 232±12 212±13 188±14 165±17 167±22 152±27 0.19 39.31** 0.89
Transplant 220±22 217±29 186±28 152±32 159±32 125±40
Timed tests (walk) Control 9.76±0.56 9.81±0.30 11.20±0.67 11.93±0.64 13.28±0.50 17.30±2.84 4.05 9.90** 2.67*
Transplant 9.38±0.34 9.98±0.47 10.66±1.38 10.05±1.06 10.12±1.34 10.40±1.57
Timed tests (hand
tap L&R)
Control 86.8±7.2 79.4±5.4 67.8±5.5 60.4±4.7 52.7±4.5 48.4±5.3 0.08 36.27** 0.79
Transplant 82.8±10.1 77.3±11.1 72.8±13.0 62.9±15.8 68.8±15.9 62.7±17.7
Timed tests (drink) Control 13.23±1.03 13.29±1.90 15.07±1.86 19.21±3.32 19.33±4.42 24.30±6.83 0.49 6.20** 1.51
Transplant 5.00±* 10.38±2.23 12.06±4.18 16.96±7.28 9.35±2.71 11.00±4.48
**p<0.001; *p<0.05 (not significant when correcting for multiple comparisons); transplant improved (+), or impaired (−) with respect to the reference controls.
UHDRS (total motor score): 0–124, 124 worse; UHDRS (functional assessment): 25–50, 50 worse; UHDRS (ADL scale): 0 worse; UHDRS (independence scale); 0–100, 0 worse,; Fahn
score: 0–13, 0 worse; Cognitive battery: 0 worse; Timed tests (walk, hand tap (l & r) and drink): 0 worse.
CAPIT, Core assessment program for intracerebral transplantations; ADL, activities of daily living; UHDRS, Unified Huntington’s Disease Rating Scale.
Note: all significant results are identified in bold.
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Table 5 CAPIT neuropsychology battery assessments
Tests Years
0–2 years (2–4 years
pre-T1)
2–4 years (0–2 years
pre-T1)
4–6 years (0–2 years
post-T1)
6–8 years (0–2 years
post-T1)
8–10 years (0–2 years
post-T1)
10–12 years (0–2 years
post-T1) Groups Time Group×Time
Mean±SEM Mean±SEM Mean±SEM Mean±SEM Mean±SEM Mean±SEM F1,15 F5,68 F5,68
Verbal fluency (letters) Control
(n=12)
31.8±1.9 31.3±2.1 30.2±2.1 27.7±3.5 25.7±3.6 23.9±5.5 0.93 7.42** 2.95
Transplant
(n=5)
299±5.2 32.0±6.3 27.8±5.9 24.1±5.6 26.4±4.1 19.5±3.0
Verbal fluency (animals) Control 15.3±1.1 14.5±1.1 14.2±1.3 11.9±1.6 11.9±2.1 11.9±2.4 0.01 15.93** 0.82
Transplant 18.0±0.9 16.2±2.8 13.1±2.2 11.4±2.0 10.2±1.2 9.0±3.0
Symbol digit Control 34.6±3.3 30.13.2 27.0±3.5 22.5±3.3 21.7±4.6 29.2±6.7 0.18 40.18** 0.49
Transplant 33.6±4.3 28.9±4.4 24.2±3.6 21.4±5.0 18.5±3.5 17.8±5.9
Stroop (colours) Control 55.7±3.0 48.8±2.9 45.8±2.9 38.4±3.5 34.0±3.3 33.7±5.1 0.08 38.70** 0.48
Transplant 51.8±5.0 51.0±6.9 44.7±7.3 37.1±8.3 35.5±9.3 33.7±10.7
Stroop (words) Control 76.4±4.7 67.7±4.9 59.8±5.4 50.7±5.3 47.0±5.7 41.3±7.3 0.09 44.63** 0.71
Transplant 70.2±6.8 71.9±8.8 58.9±7.8 44.4±8.9 45.7±10.0 42.6±10.7
Stroop Control 31.1±2.1 29.9±2.0 26.0±1.8 22.2±2.2 18.5±2.7 17.6±3.4 0.09 27.44** 0.54
(interference) Transplant 30.2±4.9 33.2±6.5 27.6±4.4 23.9±6.8 24.7±7.6 19.5±7.0
MMSE Control 28.1±0.5 27.9±0.5 27.3±0.6 27.3±0.8 25.7±1.3 25.7±1.3 0.02 10.98** 0.57
Transplant 28.1±0.4 27.9±0.7 28.0±0.5 27.4±0.9 25.1±1.2 25.5±1.8
Hopkins (test 1) Control 5.6±0.4 5.7±0.5 5.4±0.5 4.8±0.5 4.7±0.7 4.7±0.9 0.36 6.42** 0.43
Transplant 5.8±0.9 5.6±0.5 4.5±0.4 4.4±0.8 3.9±0.8 3.5±0.5
Hopkins (test 2) Control 7.4±0.4 7.4±0.6 7.1±0.5 6.7±0.6 6.9±0.7 6.5±1.2 0.12 11.42** 2.06
Transplant 8.3±0.9 7.6±0.6 6.8±1.0 5.3±0.8 5.7±0.5 5.0±1.0
Hopkins (test 3) Control 8.3±0.6 8.7±0.7 7.6±0.8 7.0±0.7 8.1±0.7 6.6±1.7 0.00 7.98** 1.97
Transplant 8.8±0.8 8.3±0.8 8.1±1.0 6.2±1.1 6.7±0.4 7.0±1.0
Hopkins (delays) Control 7.7±0.6 7.7±0.8 6.4±0.9 5.8±1.0 6.4±1.0 6.3±1.5 0.07 9.63** 0.54
Transplant 8.2±0.9 7.9±0.9 7.2±1.4 6.1±1.3 5.2±0.3 5.5±1.5
WCST (categories) Control 5.3±0.4 5.7±0.3 5.4±0.3 5.4±0.3 5.4±0.2 5.7±0.3 2.86 5.12** 4.52**
Transplant 4.7±0.8 4.9±1.0 4.6±0.9 4.5±0.7 4.3±1.1 1.5±1.5
WCST (errors) Control 6.6±2.1 6.2±1.9 6.5±1.7 7.9±2.2 6.1±1.1 4.4±2.1 2.02 4.90** 3.54*
Transplant 11.9±4.7 9.0±5.6 10.4±4.5 13.5±4.8 11.9±4.5 25.5±8.5
Trails test (form A) Control 61.8±7.1 58.6±5.3 71.6±9.60 85.9±11.6 76.9±14.5 72.7±17.3 1.01 13.62** 0.85
Transplant 67.5±16.7 72.1±13.9 88.3±20.3 90.2±30.3 112.2±20.6 110.0±57.0
Trails test (form B) Control 118.5±12.2 162.7±34.9 135.7±16.6 135.9±18.5 155.7±29.3 157.4±54.1 0.48 10.44** 0.53
Transplant 135.4±22.1 128.7±15.7 227.0±97.1 164.2±15.7 199.7±62.3 **
Recognition memory Control 10.7±0.4 10.7±0.5 10.2±0.7 10.7±0.4 10.1±0.5 10.0±0.5 0.17 0.83 0.24
Transplant 11.3±0.3 10.8±0.5 10.7±0.5 10.0±0.9 10.5±0.7 10.0±3.0
Digit span (forward) Control 7.4±0.3 7.5±0.4 7.4±0.5 6.6±0.3 7.1±0.5 6.2±0.9 0.21 9.03** 0.97
Transplant 7.5±0.4 6.6±0.4 6.9±0.9 6.8±0.7 6.0±1.1 5.8±0.8
Digit span (backward) Control 5.4±0.4 4.8±0.4 5.0±0.5 4.6±0.5 4.7±0.6 4.3±0.6 0.09 6.50** 0.46
Transplant 5.5±0.5 5.1±0.5 5.1±0.6 5.3±0.9 3.5±0.8 4.0±0.0
Rivermead (immediate) Control 7.4±0.3 7.5±0.4 7.4±0.5 6.6±0.4 7.1±0.5 6.2±0.9 0.40 5.91** 0.82
Transplant 7.5±0.4 6.6±0.4 6.9±0.8 6.8±0.7 6.0±1.1 5.8±0.8
Rivermead (delay) Control 5.4±0.4 4.8±0.4 5.0±0.5 4.6±0.5 4.7±0.6 4.3±0.6 0.03 9.42** 1.83
Transplant 5.5±0.5 5.1±0.5 5.1±0.6 5.3±0.9 3.5±0.8 4.0±0.0
Conditional associates Control 34.1±6.8 30.1±6.0 33.0±7.2 39.3±7.2 35.6±9.7 26.0±11.1 0.01 4.63** 0.85
Transplant 31.8±8.2 25.4±7.4 31.7±9.3 29.9±11.2 38.6±15.1 50.5±17.5
**p<0.001; *p<0.05 (not significant when correcting for multiple comparisons); Transplant improved (+), or impaired (−) with respect to the reference controls.
For Trails test parts A and B, and conditional associates, a LOWER scores indicates a BETTER performance. For all other tests 0 is worse.
CAPIT, Core assessment program for intracerebral transplantations; MMSE, Mini Mental State Examination; WCST, Wisconsin Card Sorting Test.
Note: all significant results are identified in bold.
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tempting to focus on apparent improvements in individual
patients on particular tests. However, although such encour-
aging signs could be identiﬁed in the present ﬁve patients, the
changes were in all cases small; similar short-term ﬂuctuations
could be identiﬁed in control patients of the reference group;
and there were no statistically signiﬁcant sustained improve-
ments in the group with transplants on any of the CAPIT neur-
ology or neuropsychology measures.
As such, the present data fails to support the efﬁcacy of the
current transplantation protocol in signiﬁcantly modifying the
course of patients’ disease. Although one conclusion might be
that cell therapy does not work in HD, this seems premature
when set alongside the clear recovery observed in animal
models30 and in some patients in other studies.6 8 It is likely
that differences between the several small open label studies
published to date assessing neural transplantation in HD, includ-
ing the present study, relate to differences in (A) patient selec-
tion, for instance, the US study used relatively advanced
patients; and (B) tissue dissection, for instance, the US study
used lateral lateral ganglionic tissue grafts, whereas others have
used whole striatal grafts and (C) tissue preparation, for
instance, the French group used tissue pieces while we used a
tissue suspension approach (for a more detailed discussion on
this, see refs 13 and 14).
Alternatively, the absence of a convincing increase here in the
post-transplantation striatal raclopride signal could relate more
to the fact that we simply did not implant sufﬁcient numbers of
cells, a major determinant of the survival and differentiation of
striatal grafts.31 A primary concern when we were ﬁrst designing
the NEST-UK trial was the possibility for embryonic striatal
tissue to overgrow. This was ﬁrst observed in some human stri-
atal xenografts in the rat brain,16 but has also been seen in at
least two clinical trials in HD patients.13 32 33 In our ﬁrst study
of safety and feasibility, we therefore undertook implants of
relatively small amounts of tissues—typically 5–10×106 cells
from two or occasionally three ganglionic eminences from one
or two donor embryos. The imaging results showed change in
FLAIR signal along the surgical tracts consistent with minor
tissue trauma. However, no signiﬁcant graft deposits could be
identiﬁed on serial imaging, using either MRI or RAC-PET.
These observations are consistent with our previous experience
with similar small graft volume protocols in rats and primates in
which the implanted tissue volume was too small to exert any
clear functional beneﬁt. Rather, the dissociated cell suspension
protocols employed here appear to be safe, but now warrant
scaling up to implant larger numbers of cells to yield grafts of
comparable size and integration to those that have been seen to
be effective in animal studies. At the same time, attention still
needs to be paid to accurate tissue dissection, since misdissection
to include any meningeal cells can yield clear overgrowth and
proliferation of non-neuronal tissues within neural grafts.13 34
There has been considerable debate about the extent to which
positive results in previous open label transplant studies—in par-
ticular in Parkinson’s disease, but also in HD—reﬂect placebo
effects when neither the subjects nor the investigators are blind
to the experimental condition. The present study is similarly
open label, and none of the testing was undertaken blind.
Nevertheless, although the present patients with grafts were
highly motivated and exhibited clinically strong expectations of
success, we saw no evidence for any clear placebo effect when
patients were assessed long-term on a well-validated CAPIT test
battery, and in spite of expectation of beneﬁt, the patients with
grafts exhibited no clear changes on test scores in comparison
with the reference control group. Rather, the motor and cogni-
tive features progressed at a very similar rate over the subse-
quent 8–10 years in both groups. A similar result has been
recorded in an otherwise negative longitudinal clinical trial of
riluzole in HD (R Roos, personal communication). Whereas we
recognise the need for well-designed double-blind placebo-
controlled studies of a candidate cell therapy just like for any
Figure 2 Mean striatal
11C-raclopride binding potential of
subjects 1–4 compared with a group
of the non-grafted Huntington’s
disease controls (n=7). T1=ﬁrst
implantation (right-sided); T2=second
implantation (left-sided); BP, binding
potential; R, Right; L, left. Error bars
indicates SDs.
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other medicinal product before it is released for widespread dis-
tribution in a standardised format, we consider that placebo
effects in open label studies can be overemphasised, and that
small case-control studies provide a more efﬁcient and cost
effective study format within which to reﬁne and optimise pro-
tocols while the methods are still at a relatively early stage of
development.35.
Although not its primary aim, the present data provide what
is probably the longest longitudinal study of functional progres-
sion in HD using standardised neurological and neuropsycho-
logical tests. For this purpose, both motor and cognitive
measures in the UHDRS offered reliable and stable measures of
disease progression. All the neurological measures and all but
one of the neuropsychological measures yielded a highly signiﬁ-
cant change across the years, as has been reported previously for
non-surgical patients from this cohort over a 3–6-year time
span.36 While recognising the invalidity of ‘concluding the null
hypothesis’, the very high values for the F ratios of the main
effects of tests (within subjects) increases the impact of the
absence of any signiﬁcant differences over time between the two
experimental groups (see tables 4 and 5). The data also attest to
the continuing utility of the UHDRS and its subscales as an
outcome measure of longitudinal progression in experimental
and clinical HD research, although the sensitivity of these mea-
sures to detect subtle changes is still unclear. By contrast,
whereas some subtests of the CANTAB battery have proved
powerful for analysing the precise proﬁle of functional impair-
ment in HD, for instance, with the demonstration of patients
particular susceptibility to impairments in extradimensional set-
shifting,37 we found the CANTAB automated touch screen mea-
sures to be less sensitive to the longitudinal progression of the
disease. A further difference is that it is only on several of the
CANTAB subtests that effects of the neurosurgical treatment
were seen to show any signiﬁcant interactions in this trial.
However, the signiﬁcant changes all involved a late-stage deteri-
oration rather than beneﬁt in the group with transplants; and
since the effects were restricted only to the last tests applied 8–
10 years post-transplantation, it is not yet clear whether this
reﬂects a stable long-term impairment in speciﬁc aspects of pre-
frontal cognition, or a late-stage decline in individual patients
close to the end of their lifespan.
In conclusion, the ﬁrst ﬁve patients in the NEST-UK tolerabil-
ity and feasibility study of striatal cell transplantation in HD
conﬁrms the absence of any long-term adverse effects and, we
conclude, based on a limited number of patients followed long-
term, that the surgical procedure is itself safe and feasible.
Moreover, we found no signiﬁcant clinical beneﬁt of cell trans-
plantation in these patients in any of the neurological, neuro-
psychological or imaging assessments. However, as a tolerability
trial, we started with a low number of cells implanted, similar to
the strategy adopted in dose escalation studies of novel pharma-
cotherapeutics, and since the imaging revealed no obvious graft
masses, the absence of efﬁcacy is not remarkable. To build on
these ﬁndings, work to establish the optimum tissue selection,
preparation and transplantation protocols are now key if efﬁcacy
is to be demonstrated. As an adjunct we have followed a group
of 12 patients without grafts from the same cohort for more
than 10 years, who showed clear and consistent progression of
disability over a longer time frame than has been systematically
evaluated hitherto. Although conducted as an open label study,
it is notable that the patients with grafts showed no evidence
whatsoever of a placebo effect, on the basis of which we can
conclude that informative pilot data on efﬁcacy can continue to
be explored in open label studies with long-term follow-up
prior to further reﬁnements in the protocols to a stage where a
fully blinded, controlled study is warranted.
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